









LASOFOXIFENE

Novel Targeted Endocrine Agent

	STUDY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	COLLABORATOR	
Breast Cancer	ELAINE-1: Laso vs. Fulvestrant (monotherapy)		Active				
	ELAINE-2: Laso+Abema		Active				
	ELAINE-3: Laso+Abema vs. Fulv+Abema		Active, not yet recruiting				
	Lasofoxifene+mTOR inhibitor		Planning				
	iSPY2: Lasofoxifene (monotherapy)		Active				
	Laso in BC patients with symptoms of urogenital atrophy (monotherapy)		Planning				
Pre-clinical studies in treatment resistant BC tumors ¹	Lasofoxifene vs. Fulvestrant (mono)	Completed					
	Laso+Palbo vs. Fulvestrant+Palbo	Completed					
	Laso, Fulv +/- Abema (mono and combo therapy)	Active					
Gynecological cancer	Lasofoxifene in endometrial cancer (mono and combo therapy)	Active					

¹ Both ESR1^{mut} and non-ESR1^{mut}